Cargando…
Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
BACKGROUND: Human species C adenovirus serotype 5 (Ad5) is the archetype oncolytic adenovirus and has been used in the vast majority of preclinical and clinical tests. While Ad5 can be robust, species C Ad6 has lower seroprevalence, side effects, and appears to be more potent as a systemic therapy a...
Autores principales: | Nguyen, Tien V, Crosby, Catherine M, Heller, Gregory J, Mendel, Zachary I, Barry, Mary E, Barry, Michael A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939883/ https://www.ncbi.nlm.nih.gov/pubmed/29765912 http://dx.doi.org/10.2147/OV.S155946 |
Ejemplares similares
-
Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers
por: Nguyen, Tien V, et al.
Publicado: (2016) -
Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5
por: Nguyen, Tien V., et al.
Publicado: (2017) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012) -
The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses
por: Tate, Sophia J., et al.
Publicado: (2021) -
Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy
por: Mahasa, Khaphetsi Joseph, et al.
Publicado: (2020)